APA (7th ed.) Citation

DS, G., EM, F., Jr, G. G., J, H., WH, L., FD, L., . . . S, v. d. N. (2002). Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]. Neurology, 58(2), 169. https://doi.org/10.1212/wnl.58.2.169

Chicago Style (17th ed.) Citation

DS, Goodin, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, and van den Noort S. "Disease Modifying Therapies in Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]." Neurology 58, no. 2 (2002): 169. https://doi.org/10.1212/wnl.58.2.169.

MLA (9th ed.) Citation

DS, Goodin, et al. "Disease Modifying Therapies in Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]." Neurology, vol. 58, no. 2, 2002, p. 169, https://doi.org/10.1212/wnl.58.2.169.